- Speaker
Benny Yang, PhD
Chief Scientific Officer & Head of Drug Discovery of Biocytogen
- Title
Fully Human Antibody Therapeutics on RenMab Discovery Platform - A Snapshot of Project Integrum
- Time
- May 28, 2020 1:00 pm
- Abstract
- 1. In vivo antibody discovery using transgenic/humanized mice is of rising importance for the antibody community as it offers a multitude of benefits over in vitro methods. 2. Benefits of in vivo method for antibody discovery and latest technical data including affinity and antibody repertoire analysis for RenMab™ Antibodies. 3. Brief communication of RenMab Mouse in the production of anti-SARS-CoV-2 antibodies as an on-going project. 4. Development of RenMab platform to address difficult target (such as GPCR) through “RenMab + target knockout” (Project Integrum), as well as novel fully human antibody mice for bispecific and single-domain antibodies, respectively
An Innovative Platform of Biocytogen